Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on developing novel immunology therapeutics derived from its research into transfer RNA synthetase (tRS) biology. The company operates within the biopharmaceutical and immunology industries, with a core emphasis on addressing immune-mediated and inflammatory diseases that have limited treatment options. Its scientific platform is based on discoveries that fragments of tRNA synthetases play regulatory roles in immune signaling beyond their traditional function in protein synthesis.
The company’s primary revenue driver is research and development activity, as it does not currently generate product sales. aTyr Pharma’s lead product candidate is efzofitimod (ATYR1923), an immunomodulatory fusion protein designed to selectively modulate neuropilin-2–mediated immune responses. The company was founded in 2005 and has evolved from a discovery-stage enterprise into a clinical-stage organization, advancing its lead candidate into mid-stage clinical trials while refining its broader tRS-based discovery platform.
Business Operations
aTyr Pharma conducts its operations as a single-reportable operating segment focused on drug discovery and clinical development. The company’s activities center on advancing efzofitimod, which is being developed primarily for pulmonary sarcoidosis, an orphan inflammatory lung disease. Revenue generation to date has consisted of collaboration-related income and grant funding rather than commercial product sales.
The company’s core assets include its tRNA synthetase-based discovery platform, proprietary protein engineering capabilities, and clinical data generated from completed and ongoing trials. aTyr Pharma has historically engaged in strategic research collaborations, including past partnerships with large pharmaceutical companies, though it currently retains full rights to its lead clinical program. Operations are primarily conducted internally with support from contract research organizations for clinical trials and manufacturing.
Strategic Position & Investments
Strategically, aTyr Pharma is focused on advancing efzofitimod through clinical development while leveraging its platform to identify additional immunomodulatory biologics. Growth initiatives center on expanding clinical indications for efzofitimod, pursuing regulatory pathways for orphan diseases, and selectively advancing earlier-stage discovery programs derived from its tRS biology insights.
The company has made targeted investments in clinical trials, biomarker development, and translational research rather than broad acquisitions. aTyr Pharma does not maintain a diversified portfolio of commercial subsidiaries; instead, it operates with a lean structure aimed at maximizing capital efficiency. Its strategic positioning emphasizes differentiation through a novel mechanism of action in immunology, which management believes may offer advantages over conventional anti-inflammatory or immunosuppressive therapies.
Geographic Footprint
aTyr Pharma is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is primarily domestic, encompassing corporate management, research oversight, and clinical program leadership within the U.S.
Internationally, aTyr Pharma’s presence is mainly indirect, achieved through global clinical trial sites and third-party vendors supporting studies conducted in North America and Europe. While the company does not maintain significant physical operations outside the U.S., its clinical development strategy has an international scope aligned with regulatory requirements and patient recruitment needs in multiple regions.
Leadership & Governance
aTyr Pharma is led by an executive team with experience in biotechnology, clinical development, and corporate strategy. The company’s leadership emphasizes scientific rigor, disciplined capital allocation, and advancing differentiated immunology therapies through clearly defined clinical milestones.
Key executives include:
- Sanjay S. Shukla – President and Chief Executive Officer
- Paul Schimmel – Ph.D., Co‑Founder and Chairman of the Board
- Mark W. Harvey – Chief Financial Officer
- Leslie A. Williams – Chief Operating Officer
- Bruce A. Beutler – M.D., Scientific Founder and Advisor
The board and management team guide the company with a strategic vision centered on translating foundational biology into clinically meaningful therapies, while maintaining governance practices aligned with U.S. public company standards.